Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Dacogen in Low/Int-1 Risk MDS
NCT00619099Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2008
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in myelodysplastic syndrome (MDS), sponsored by Eisai Co., Ltd.. Started May 2008; status: completed.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00619099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00619099.